-+ 0.00%
-+ 0.00%
-+ 0.00%

Germany's Formycon Adopts AI Technologies to Optimize Biosimilar Development

MT Newswires·10/06/2026 01:23:45
Listen to the news
01:23 AM EDT, 10/06/2026 (MT Newswires) -- Formycon (FYB.F) is expanding its use of artificial intelligence and other digital technologies to improve the efficiency of biosimilar development under its FYB4GROWTH strategy. The German biosimilar developer said Tuesday it is introducing Phlexglobal's artificial intelligence-supported electronic trial master file platform as a central system for current and future clinical development activities. Formycon has also deployed AI-based software to analyze manufacturing process data to boost collaboration with contract manufacturers and support assessments of critical quality attributes.